Is There a Mendelian Transmission Ratio Distortion of the C.429 452Dup(24Bp) Polyalanine Tract ARX Mutation?
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
D-Penicillamine-Induced Status Dystonicus in a Patient with Wilson’S Disease: a Diagnostic & Therapeutic Challenge
A. Satyasrinivas, et al. D-penicillamine-induced Status Dystonicus | Case Report D-penicillamine-induced Status Dystonicus in A Patient with Wilson’s Disease: A Diagnostic & Therapeutic Challenge A. Satyasrinivas*, Y.S. Kanni, N.Rajesh, M.SaiSravanthi, Vijay kumar Department of General Medicine, Kamineni Institute Of Medical Sciences, Narketpally 508254 Andhra Pradesh, India. DOI Name http://dx.doi.org/10.3126/jaim.v3i2.14066 Keywords Dystonia,Gabapentin Kayser-Fleischer ring, ABSTRACT Trientein hydrochloride, Wilson’s disease. Wilson's disease is an autosomal-recessive disorder of copper metabolism Citation resulting from the absence or dysfunction of a copper-transporting protein. A. Satyasrinivas, Y.S. Kanni, N.Rajesh, The disease is mainly seen in children, adolescents and young adults, and is M.SaiSravanthi, Vijay kumar. D-penicillamine- induced Status Dystonicus in A Patient with characterized by hepatobiliary, neurologic, psychiatric and ophthalmologic Wilson’s Disease: A Diagnostic & Therapeutic (Kayser-Fleischer rings) manifestations. Mechanism of status dystonicus in WD Challenge. Journal of Advances in Internal Medicine is not clear We present here a case study of Wil. son’s disease in 14 year old 2014;03(01):62-64. child with dystonia not responed with routine therapy. INTRODUCTION but patient had developed loose stools, difficulty in speaking and pronouncing linguals. With these compliants he was Wilson’s disease (WD), also known as hepatolenticular admitted in the hospital. On Radio imaging and ophthalmic degeneration was first described in 1912 by Kinnear Wilson as examination he was diagnosed as a case of Wilson’s disease progressive lenticular degeneration. WD is an inherited, fatal and was started with tablet calcium Pantothenate and neurological disorder accompanied by chronic liver disease tablets D-Penicillamine and was discharged. -
Childhood Epilepsy: an Update on Diagnosis and Management
American Journal of Neuroscience Review Childhood Epilepsy: An Update on Diagnosis and Management Khaled Saad Department of Pediatrics, Faculty of Medicine, University of Assiut, Assiut 71516, Egypt Article history Abstract: Within the past few years there is a rapid expansion in our Received: 23-10-2014 understanding of epilepsy. The development of new anti-epileptic drugs and Revised: 25-11-2014 refinements to epilepsy surgery are widening the therapeutic options for Accepted: 12-01-2015 epilepsy. In addition, the classification of the epilepsies continues to evolve based on an increased understanding of the molecular genetics of the condition and this includes the recognition of possible novel epilepsy syndromes. This review considers some of these exciting developments, as well as addressing the essential features of the diagnosis, investigations, management and impact of epilepsy in childhood. Keywords: Children, Epilepsy, Seizure, Anti-Epileptic Drugs Introduction guidelines for optimal practices, rational therapy and counseling (Aylwad, 2008; Tamber and Mountz, 2012; Epilepsy is a common heterogeneous neurological Sharma, 2013). problem in children. It exerts a significant physical, psychological, economic and social toll on children and Definitions their caregivers. Fifty million people have epilepsies A seizure is defined as an excessive burst of abnormal globally; more than half of them are children. In the synchronized neuronal activity affecting small or large USA; between 25,000 and 40,000 children will have a neuronal networks that results in clinical manifestations first non-febrile seizure each year. The problem is that are sudden, transient and usually brief. Epilepsy is further compounded in developing countries as they add defined as a disorder of the brain characterized by any of about 75-80% of new cases of epilepsy (Guerrini, 2006; the following conditions: (1) At least two unprovoked (or Tamber and Mountz, 2012; Sharma, 2013). -
Causes of Mortality in Early Infantile Epileptic Encephalopathy: a Systematic Review
Epilepsy & Behavior 85 (2018) 32–36 Contents lists available at ScienceDirect Epilepsy & Behavior journal homepage: www.elsevier.com/locate/yebeh Review Causes of mortality in early infantile epileptic encephalopathy: A systematic review Graciane Radaelli a,b, Francisco de Souza Santos b, Wyllians Vendramini Borelli b,LeonardoPisanib, Magda Lahorgue Nunes b,d, Fulvio Alexandre Scorza c,d, Jaderson Costa da Costa b,d,⁎ a Federal University of São Paulo (UNIFESP)/Paulista School of Medicine, São Paulo, Brazil b Brain Institute of Rio Grande do Sul (BraIns), Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, RS, Brazil c Laboratory of Neuroscience, Department of Neurology and Neurosurgery, Federal University of São Paulo, São Paulo, SP, Brazil d CNPq, Brazil article info abstract Article history: Introduction: Early infantile epileptic encephalopathy syndrome (EIEE), also known as Ohtahara syndrome, is an Received 6 March 2018 age-dependent epileptic encephalopathy syndrome defined by clinical features and electroencephalographic Revised 25 April 2018 findings. Epileptic disorders with refractory seizures beginning in the neonatal period and/or early infancy Accepted 5 May 2018 have a potential risk of premature mortality, including sudden death. We aimed to identify the causes of death Available online xxxx in EIEE and conducted a literature survey of fatal outcomes. Methods: We performed a literature search in MEDLINE, EMBASE, and Web of Science for data from inception Keywords: “ ”“ ”“ ”“ ” “ ” Ohtahara syndrome until September 2017. The terms death sudden, unexplained death, SUDEP, lethal, and fatal and the “ ”“ ”“ ”“ Early infantile epileptic syndrome medical subject heading terms epileptic encephalopathy, mortality, death, sudden infant death syn- Suppression burst drome,” and “human” were used in the search strategy. -
Consensus Guideline for the Diagnosis and Treatment of Aromatic L-Amino
Wassenberg et al. Orphanet Journal of Rare Diseases (2017) 12:12 DOI 10.1186/s13023-016-0522-z REVIEW Open Access Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency Tessa Wassenberg1, Marta Molero-Luis2, Kathrin Jeltsch3, Georg F. Hoffmann3, Birgit Assmann3, Nenad Blau4, Angeles Garcia-Cazorla5, Rafael Artuch2, Roser Pons6, Toni S. Pearson7, Vincenco Leuzzi8, Mario Mastrangelo8, Phillip L. Pearl9, Wang Tso Lee10, Manju A. Kurian11, Simon Heales12, Lisa Flint13, Marcel Verbeek1,14, Michèl Willemsen1 and Thomas Opladen3* Abstract Aromatic L-amino acid decarboxylase deficiency (AADCD) is a rare, autosomal recessive neurometabolic disorder that leads to a severe combined deficiency of serotonin, dopamine, norepinephrine and epinephrine. Onset is early in life, and key clinical symptoms are hypotonia, movement disorders (oculogyric crisis, dystonia, and hypokinesia), developmental delay, and autonomic symptoms. In this consensus guideline, representatives of the International Working Group on Neurotransmitter Related Disorders (iNTD) and patient representatives evaluated all available evidence for diagnosis and treatment of AADCD and made recommendations using SIGN and GRADE methodology. In the face of limited definitive evidence, we constructed practical recommendations on clinical diagnosis, laboratory diagnosis, imaging and electroencephalograpy, medical treatments and non-medical treatments. Furthermore, we identified topics for further research. We believe this guideline will improve the care for AADCD patients around the world whilst promoting general awareness of this rare disease. Keywords: Aromatic l-amino acid decarboxylase deficiency, AADC deficiency, Neurotransmitter, Dopamine, Serotonin, Guideline, Infantile dystonia-parkinsonism, SIGN, GRADE German abstract Der Aromatische L-Aminosäuren Decarboxylase Mangel (AADCD) ist eine seltene autosomal rezessive neurometabolische Störung, die zu einem schweren kombinierten Mangel an Serotonin, Dopamin, Norepinephrin und Epinephrin führt. -
2010 Buenos Aires, Argentina
Claiming CME Credit To claim CME credit for your participation in the MDS 14th Credit Designation International Congress of Parkinson’s Disease and Movement The Movement Disorder Society designates this educational Disorders, International Congress participants must complete activity for a maximum of 35 AMA PRA Category 1 Credits™. and submit an online CME Request Form. This form will be Physicians should only claim credit commensurate with the available beginning June 15. extent of their participation in the activity. Instructions for claiming credit: If you need a Non-CME Certificate of Attendance, please tear • After June 15, visit the MDS Web site. out the Certificate in the back of this Program and write in • Log in after reading the instructions on the page. You will your name. need your International Congress File Number which is located on your name badge or e-mail The Movement Disorder Society has sought accreditation from [email protected]. the European Accreditation Council for Continuing Medical • Follow the on-screen instructions to claim CME Credit for Education (EACCME) to provide CME activity for medical the sessions you attended. specialists. The EACCME is an institution of the European • You may print your certificate from your home or office, or Union of Medical Specialists (UEMS). For more information, save it as a PDF for your records. visit the Web site: www.uems.net. Continuing Medical Education EACCME credits are recognized by the American Medical The Movement Disorder Society is accredited by the Association towards the Physician’s Recognition Award (PRA). Accreditation Council for Continuing Medical Education To convert EACCME credit to AMA PRA category 1 credit, (ACCME) to provide continuing medical education for contact the AMA online at www.ama-assn.org. -
Case Reports Reversal of Status Dystonicus After Relocation of Pallidal Electrodes in DYT6 Generalized Dystonia
Freely available online Case Reports Reversal of Status Dystonicus after Relocation of Pallidal Electrodes in DYT6 Generalized Dystonia 1*{ 2,3{ 4 1 4 2,5 D.L. Marinus Oterdoom , Martje E. van Egmond , Luisa Cassini Ascencao , J. Marc C. van Dijk , Assel Saryyeva , Martijn Beudel , 4 6,7 4 2 2 4 Joachim Runge , Tom J. de Koning , Mahmoud Abdallat , Hendriekje Eggink , Marina A.J. Tijssen , Joachim K. Krauss 1 Department of Neurosurgery, University of Groningen, University Medical Center Groningen, the Netherlands, 2 Department of Neurology, University of Groningen, University Medical Center Groningen, the Netherlands, 3 Ommelander Ziekenhuis Groningen, Department of Neurology, Delfzijl and Winschoten, the Netherlands, 4 Department of Neurosurgery, Hannover Medical School, Germany, 5 Department of Neurology, Isala Klinieken, Zwolle, the Netherlands, 6 Department of Pediatrics, University of Groningen, University Medical Center Groningen, the Netherlands, 7 Department of Genetics, University of Groningen, University Medical Center Groningen, the Netherlands Abstract Background: DYT6 dystonia can have an unpredictable clinical course and the result of deep brain stimulation (DBS) of the internal part of the globus pallidus (GPi) is known to be less robust than in other forms of autosomal dominant dystonia. Patients who had previous stereotactic surgery with insufficient clinical benefit form a particular challenge with very limited other treatment options available. Case Report: A pediatric DYT6 patient unexpectedly deteriorated to status dystonicus 1 year after GPi DBS implantation with good initial clinical response. After repositioning the DBS electrodes the status dystonicus resolved. Discussion: This case study demonstrates that medication-resistant status dystonicus in DYT6 dystonia can be reversed by relocation of pallidal electrodes. -
Neonatal Seizures Revisited
children Review Neonatal Seizures Revisited Konrad Kaminiów 1 , Sylwia Kozak 1 and Justyna Paprocka 2,* 1 Students’ Scientific Society, Department of Pediatric Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland; [email protected] (K.K.); [email protected] (S.K.) 2 Department of Pediatric Neurology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland * Correspondence: [email protected] Abstract: Seizures are the most common neurological disorder in newborns and are most prevalent in the neonatal period. They are mostly caused by severe disorders of the central nervous system (CNS). However, they can also be a sign of the immaturity of the infant’s brain, which is characterized by the presence of specific factors that increase excitation and reduce inhibition. The most common disorders which result in acute brain damage and can manifest as seizures in neonates include hypoxic-ischemic encephalopathy (HIE), ischemic stroke, intracranial hemorrhage, infections of the CNS as well as electrolyte and biochemical disturbances. The therapeutic management of neonates and the prognosis are different depending on the etiology of the disorders that cause seizures which can lead to death or disability. Therefore, establishing a prompt diagnosis and implementing appropriate treatment are significant, as they can limit adverse long-term effects and improve outcomes. In this review paper, we present the latest reports on the etiology, pathomechanism, clinical symptoms and guidelines for the management of neonates with acute symptomatic seizures. Keywords: neonatal seizures; pathophysiology; genetics; inborn errors of metabolism Citation: Kaminiów, K.; Kozak, S.; Paprocka, J. -
Movement Disorder Emergencies 1 4 Robert L
Movement Disorder Emergencies 1 4 Robert L. Rodnitzky Abstract Movement disorders can be the source of signifi cant occupational, social, and functional disability. In most circumstances the progression of these disabilities is gradual, but there are circumstances when onset is acute or progression of a known movement disorders is unexpectedly rapid. These sudden appearances or worsening of abnormal involuntary movements can be so severe as to be frightening to the patient and his family, and disabling, or even fatal, if left untreated. This chapter reviews movement disorder syndromes that rise to this level of concern and that require an accurate diagnosis that will allow appropriate therapy that is suffi cient to allay anxiety and prevent unnecessary morbidity. Keywords Movement disorders • Emergencies • Acute Parkinsonism • Dystonia • Stiff person syndrome • Stridor • Delirium severe as to be frightening to the patient and his Introduction family, and disabling, or even fatal, if left untreated. This chapter reviews movement disor- Movement disorders can be the source of signifi - der syndromes that rise to this level of concern cant occupational, social, and functional disabil- and that require an accurate diagnosis that will ity. In most circumstances the progression of allow appropriate therapy that is suffi cient to these disabilities is gradual, but there are circum- allay anxiety and prevent unnecessary morbidity. stances when onset is acute or progression of a known movement disorders is unexpectedly rapid. These sudden appearances or worsening Acute Parkinsonism of abnormal involuntary movements can be so The sudden or subacute onset of signifi cant par- R. L. Rodnitzky , MD (*) kinsonism, especially akinesia, is potentially very Neurology Department , Roy J. -
(12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub
US 2010O2.10567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub. Date: Aug. 19, 2010 (54) USE OF ATUFTSINASATHERAPEUTIC Publication Classification AGENT (51) Int. Cl. A638/07 (2006.01) (76) Inventor: Dorian Bevec, Germering (DE) C07K 5/103 (2006.01) A6IP35/00 (2006.01) Correspondence Address: A6IPL/I6 (2006.01) WINSTEAD PC A6IP3L/20 (2006.01) i. 2O1 US (52) U.S. Cl. ........................................... 514/18: 530/330 9 (US) (57) ABSTRACT (21) Appl. No.: 12/677,311 The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for (22) PCT Filed: Sep. 9, 2008 the prophylaxis and/or treatment of cancer, autoimmune dis eases, fibrotic diseases, inflammatory diseases, neurodegen (86). PCT No.: PCT/EP2008/007470 erative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the S371 (c)(1), present invention relates to pharmaceutical compositions (2), (4) Date: Mar. 10, 2010 preferably inform of a lyophilisate or liquid buffersolution or artificial mother milk formulation or mother milk substitute (30) Foreign Application Priority Data containing the peptide Thr-Lys-Pro-Arg-OH optionally together with at least one pharmaceutically acceptable car Sep. 11, 2007 (EP) .................................. O7017754.8 rier, cryoprotectant, lyoprotectant, excipient and/or diluent. US 2010/0210567 A1 Aug. 19, 2010 USE OF ATUFTSNASATHERAPEUTIC ment of Hepatitis BVirus infection, diseases caused by Hepa AGENT titis B Virus infection, acute hepatitis, chronic hepatitis, full minant liver failure, liver cirrhosis, cancer associated with Hepatitis B Virus infection. 0001. The present invention is directed to the use of the Cancer, Tumors, Proliferative Diseases, Malignancies and peptide compound Thr-Lys-Pro-Arg-OH (Tuftsin) as a thera their Metastases peutic agent for the prophylaxis and/or treatment of cancer, 0008. -
Pediatric Disorders
Neurological Disorder Part 3 - Pediatric Disorders CDKL5 Disorder • Characteristics: • Rare x-linked genetic disorder • CDLK5 mutations cause deficiencies in the protein needed for normal brain development • More common in females; however males with the disorder are affected much more severely than females © Trusted Neurodiagnostics Academy CDKL5 Disorder • Characteristics • CDKL5D mutations can be found in children who have been diagnosed with infantile spasms, Lennox Gastaut syndrome, Rett Syndrome, West Syndrome and autism © Trusted Neurodiagnostics Academy CDKL5 Disorder • Symptoms: • Infantile spasms beginning the first 3 - 6 months of life • Neurodevelopmental impairment • Patients cannot walk, talk, or feed themselves • Repetitive hand movements (stereotypies) © Trusted Neurodiagnostics Academy CDKL5 Disorder • Seizures: • Early onset • Infantile spasms, myoclonic, tonic, tonic-clonic seizures • Status epilepticus and non convulsive status epilepticus can occur © Trusted Neurodiagnostics Academy CDKL5 Disorder • Diagnosis: • Genetic blood testing to confirm the change or mutation on the CDKL5 gene • EEG © Trusted Neurodiagnostics Academy CDKL5 Disorder • EEG Findings: • Early in the disorder • EEG may be normal or slightly abnormal • During progression of the disorder • Some background activity is slow and epileptic discharges can be seen in one or more areas • Burst Suppression • Atypical hypsarrhythmia © Trusted Neurodiagnostics Academy CDKL5 Disorder © Trusted Neurodiagnostics Academy CDKL5 Disorder • Treatment: • Seizures -
Botulinum Neurotoxin Injections in Childhood Opisthotonus
toxins Article Botulinum Neurotoxin Injections in Childhood Opisthotonus Mariam Hull 1,2,* , Mered Parnes 1,2 and Joseph Jankovic 2 1 Section of Pediatric Neurology and Developmental Neuroscience, Texas Children’s Hospital and Baylor College of Medicine, Houston, TX 77030, USA; [email protected] 2 Parkinson’s Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA; [email protected] * Correspondence: [email protected] Abstract: Opisthotonus refers to abnormal axial extension and arching of the trunk produced by excessive contractions of the paraspinal muscles. In childhood, the abnormal posture is most often related to dystonia in the setting of hypoxic injury or a number of other acquired and genetic etiologies. The condition is often painful, interferes with ambulation and quality of life, and is challenging to treat. Therapeutic options include oral benzodiazepines, oral and intrathecal baclofen, botulinum neurotoxin injections, and deep brain stimulation. Management of opisthotonus within the pediatric population has not been systematically reviewed. Here, we describe a series of seven children who presented to our institution with opisthotonus in whom symptom relief was achieved following administration of botulinum neurotoxin injections. Keywords: opisthotonus; opisthotonos; axial dystonia; botulinum toxin Key Contribution: This is the first series of pediatric patients with opisthotonus treated with bo- tulinum neurotoxin injections. Botulinum neurotoxin injections should be added to the armamentar- ium of treatment options in children with axial dystonia, including opisthotonos. Citation: Hull, M.; Parnes, M.; 1. Introduction Jankovic, J. Botulinum Neurotoxin Injections in Childhood Opisthotonus. Opisthotonus, derived from the Greek “opistho” meaning behind and “tonos” mean- Toxins 2021, 13, 137. -
Movement Disorders Emergencies: a Review Emergências Em Distúrbios Do Movimento: Uma Revisão Renato P
VIEWS AND REVIEWS Movement disorders emergencies: a review Emergências em distúrbios do movimento: uma revisão Renato P. Munhoz1,2, Mariana Moscovich1, Patrícia Dare Araujo1, Hélio A. G. Teive2 ABSTRACT Movement disorders (MD) encompass acute and chronic diseases characterized by involuntary movements and/or loss of control or ef- ficiency in voluntary movements. In this review, we covered situations in which the main manifestations are MDs that pose significant risks for acute morbidity and mortality. The authors examine literature data on the most relevant MD emergencies, including those related to Parkinson`s disease, acute drug reactions (acute dystonia, neuroleptic malignant syndrome, serotonergic syndrome and malignant hyper- thermia), acute exacerbation of chronic MD (status dystonicus), hemiballism and stiff-person syndrome, highlighting clinical presentation, demographics, diagnosis and management. Key words: movements disorders, dystonia, neuroleptic malignant syndrome, serotonergic syndrome, malignant hyperthermia, status dystonicus, dyskinesias, stiff person syndrome. RESUMO Os distúrbios do movimento (DM) englobam doenças agudas e crônicas caracterizadas por movimentos involuntários e/ou perda do controle ou eficiência em movimentos voluntários. Nesta revisão, incluímos situações nas quais as principais manifestações são DM que represen- tam risco devido à alta morbidade e mortalidade. Os autores revisaram aspectos relacionados às principais emergências em DM, incluindo aquelas relacionadas a doença de Parkinson; reações causadas por drogas (distonia aguda, síndrome neuroléptica maligna, síndrome se- rotoninérgica, hipertermia maligna); exacerbação aguda de DM crônicos (status distonicus); hemibalismo e síndrome da pessoa rígida. São destacados a apresentação clínica, os dados demográficos, o diagnóstico e o tratamento. Palavras-Chave: distúrbios de movimentos, distonia, síndrome maligna neuroléptica, síndrome serotoninérgica, hipetermia maligna, status distonicus, discinesias, síndrome da pessoa rígida.